Umifenovir did not show superior clinical outcomes when added to Favipiravir treatment. The trial did not meet key end-points ... Oct 21
Glenmark the first company to launch Favipiravir in India now launches 400 mg tablets... Aug 06
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India... Jul 13
CSIR and Laxai Sciences to seek regulatory approval for clinical trials on COVID-19 patients using combinations of antiviral and host-directed therapies... Jul 08
Glenmark is the first pharmaceutical company in India to receive approval for antiviral Favipiravir for mild to moderate covid patients... Jun 20
Phase 3 Trials will be carried out at King George’s Medical University, Dr Ram Manohar Lohia Institute and Lucknow Medical College... Jun 19
Glenmark to commence phase 3 clinical trial to test combined efficacy Favipiravir and Umifenovir ... May 26
Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India... May 26
-Advertisements-
Thursday, May 02, 2024
.jpeg)
.jpg)
